Data Releases
Expanded pathway coverage
We’ve significantly expanded our human pathways coverage by integrating additional data from the Pathbank database into three existing tables: 'pathways', 'pathways_enzymes', and 'pathways_drugs'. This update adds approximately 112,000 pathways, representing a 230% increase in total available pathways.
This expanded coverage enables more comprehensive pathway analyses, allowing you to map targets and drugs across a much broader biological landscape directly within DrugBank.
Addition of protein family data from Pfam database
We’ve added protein family data through the addition of four new tables: 'pfams', 'pfam_clans', 'pfam_clan_memberships', and 'polypeptide_pfam'. These tables allow you to link proteins in DrugBank to specific Pfam clans and families via UniProt IDs.
This update enables deeper biological context and analysis regarding structural and sequence similarities, and enables protein grouping by domain family to identify functional patterns and ‘druggable’ protein families.
Increased bioentity coverage
We’ve expanded our bioentity coverage beyond proteins linked to a drug to comprehensive coverage of the human proteome. By adding approximately 16,500 new proteins (a 250% increase) our data now includes every Swiss-Prot-reviewed human protein entry available in UniProt. This update enables exploration of undrugged proteins and supports more complete bioentity coverage.
Enhanced coverage and filterability of investigational drugs
We’ve made a significant update to our coverage of investigational drugs by adding drugs derived from the last five years of drug intervention trials on ClinicalTrials.gov. This update adds approximately 7,500 investigational drugs (a 40% increase) and continues to add new entries within days of appearing on ClinicalTrials.gov. We’ve also introduced a new 'card_type' column to the 'drugs' table that stratifies drug cards into one of two types based on their content and utility. You can learn more about Card Types in our Support Center.
This improvement provides rapid and comprehensive coverage of investigational drugs, enabling a greater view of drugs across their lifecycle and exploration of therapeutic areas earlier in the pipeline.
Increased clinical trial coverage
We’ve expanded our clinical trial coverage to include every drug intervention trial registered in ClinicalTrials.gov, regardless of whether the drug is already indexed in DrugBank. This update adds approximately 40,000 trials to the ‘clinical_trials’ table, along with their corresponding data in associated tables, representing a 20% increase in trial coverage.
These additions provide broader visibility into the clinical pipeline, enabling you to investigate trials into emerging drug interventions at the earliest possible stage.
Comprehensive restructuring of condition hierarchy
This update introduces a significant improvement of our conditions hierarchy by organizing all entries into distinct disease and non-disease areas. We've enriched the parent-child relationships in the ‘condition_children’ table in order to better align with standard medical ontologies such as MeSH and unify fragmented naming conventions, ensuring more accurate retrieval of disease areas and their subtypes.
These changes enhance how our data maps to external vocabularies and optimizes navigation for users exploring our data via interface or retrieving it programmatically. This restructure improves data reliability to ensure more exhaustive and reliable search results.
Addition of drug revocation table
This update adds a new table, 'drug_revocations', that contains records of drug entries that have been revoked from DrugBank.
Addition of 781 new drugs derived from International Nonproprietary Names (INN)
This releases introduces another batch of 781 new experimental drugs into DrugBank, all of which have been granted International Nonproprietary Names (INN).
Addition of references for structured drug indications
This update adds a new referencer_type (StructuredIndication) to citation tables and a new column to the ‘structured_indications’ table ('reference_id'). These features allow each indication to be linked back to the source from which it was identified.
Addition of disease/non-disease filtering on conditions
This update adds two additional fields to the ‘conditions’ table. The ‘is_disease’ field is a Boolean flag that indicates whether or not a given condition is a human disease, and ‘is_disease_source' provides a source for the classification (e.g. manual curation).
Enhanced mapping of conditions to other vocabularies
This update enhances the mapping between DrugBank’s conditions data and external biomedical ontologies (e.g. MedDRA) by mapping multiple identifiers per vocabulary, where appropriate. This change should facilitate more complete mapping to, and integration with, other biomedical ontologies.
For CSV data, a new table ('condition_external_identifiers') has been added. For JSON and XML data, a new field has been added to conditions which contains an array of all available identifiers.
Expanded RxCUI coverage
This update adds new product-level (SBD, SCD) and package-level (BPCK, GPCK) term types, and enhances coverage of existing RxCUI term types. It adds ~25,000 additional mappings between RxCUIs and DrugBank product concepts.
Addition of condition hierarchy
This release adds a new table, ‘condition_children’, that establishes parent-child relationships between conditions in the conditions table.
Addition of 500 new drugs derived from International Nonproprietary Names (INN)
This releases introduces another batch of 500 new experimental drugs into DrugBank, all of which have been granted International Nonproprietary Names (INN).
Addition of 500 new drugs derived from International Nonproprietary Names (INN)
This release introduces 500 new experimental drugs into DrugBank, all of which have been granted International Nonproprietary Names (INN).